[
Abdel R.A.T., S. Hafez, S. Abdelhakam, Z. Ali-Eldin, I. Esmat, M. Elsayed and A. Aboul-Fotouh. 2010. Antimicrobial resistant bacteria among health care workers in intensive care units at Ain Shams University Hospitals. J. Egypt. Soc. Parasitol. 40(1): 71.
]Search in Google Scholar
[
Al-Tawfiq J.A. 2007. Occurrence and antimicrobial resistance pattern of inpatient and outpatient isolates of Pseudomonas aeruginosa in a Saudi Arabian hospital: 1998–2003. Int. J. Infect. Dis. 11(2): 109–114.
]Search in Google Scholar
[
Andrews J.M. 2001. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48(suppl. 1): 5–16.10.1093/jac/48.suppl_1.511420333
]Search in Google Scholar
[
Ashour H.M. and A. El-Sharif. 2009. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. J. Transl. Med. 7: 14.10.1186/1479-5876-7-14265485419228413
]Search in Google Scholar
[
Ayala J., A. Quesada, S. Vadillo, J. Criado and S. Píriz. 2005. Penicillin-binding proteins of Bacteroides fragilis and their role in the resistance to imipenem of clinical isolates. J. Med. Microbiol. 54(11): 1055–1064.
]Search in Google Scholar
[
Barbosa T.M. and S.B. Levy. 2000. The impact of antibiotic use on resistance development and persistence. Drug Resist. Updat. 3(5): 303–311.
]Search in Google Scholar
[
Benčić I. and D. Baudoin. 2001. Imipenem consumption and Gramnegative pathogen resistance to imipenem at Sestre Milosrdnice University Hospital. Acta Clin. Croat. 40: 185–189.
]Search in Google Scholar
[
Brown P.D. and A. Izundu. 2004. Antibiotic resistance in clinical isolates of Pseudomonas aeruginosa in Jamaica. Rev. Panam. Salud. Publica 16(2): 125–130.
]Search in Google Scholar
[
Casal M., M. Causse, F. Rodriguez-Lopez and M. Casal. 2012. Antimicrobial resistance in clinical patterns of Pseudomonas aeruginosa (in Spanish). Rev. Esp. Quimioter. 25(1): 37–41.
]Search in Google Scholar
[
Clinical Laboratory Standards Institute (CLSI). 2015. Performance Standards for Antimicrobial Susceptibility Testing; TwentyFifth Informational Supplement (M100-S25). Clinical Laboratory Standards Institute. Wayne, Pennsylvania, USA.
]Search in Google Scholar
[
Danel F., L.M. Hall, B. Duke, D. Gur and D.M. Livermore. 1999. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob. Agents. Chemother. 43(6): 1362–1366.
]Search in Google Scholar
[
Decousser J.W., P. Pina, F. Picot, C. Delalande, B. Pangon, P. Courvalin and P. Allouch. 2003. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J. Antimicrob. Chemother. 51(5): 1213–1222.10.1093/jac/dkg20112697655
]Search in Google Scholar
[
Driscoll J.A., S.L. Brody and M.H. Kollef. 2007. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67(3): 351–368.10.2165/00003495-200767030-0000317335295
]Search in Google Scholar
[
Drissi M., Z.B. Ahmed, B. Dehecq, R. Bakour, P. Plesiat and D. Hocquet. 2008. Antibiotic susceptibility and mechanisms of betalactam resistance among clinical strains of Pseudomonas aeruginosa: first report in Algeria. Med. Mal. Infect. 38(4): 187–191.
]Search in Google Scholar
[
Dubois V., C. Arpin, M. Melon, B. Melon, C. Andre, C. Frigo and C. Quentin. 2001. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of β-lactam resistance. J. Clin. Microbiol. 39(6): 2072–2078.10.1128/JCM.39.6.2072-2078.20018809111376037
]Search in Google Scholar
[
El-Behedy E.M., H. Mohtady, N. Mohamed, F. Amer, H. El Zanfaly, D. Soud, S. Khalil, Y. El Hendy, T. El Behedy and E. El Gendy. 2002. Incidence of resistance to imipenem among hospital strains of Pseudomonas aeruginosa and surveillance for blaIMP gene. Egypt. J. Med. Microbiol. 13(3): 565–572.
]Search in Google Scholar
[
El-Kholy A., H. Baseem, G.S. Hall, G.W. Procop and D.L. Longworth. 2003. Antimicrobial resistance in Cairo, Egypt 1999– 2000: a survey of five hospitals. J. Antimicrob. Chemother. 51(3): 625–630.10.1093/jac/dkg10112615864
]Search in Google Scholar
[
El-Kholy A., T. Saied, M. Gaber, M. A. Younan, M. Haleim, H. El-Sayed, H. El-Karaksy, H. Bazara’a and M. Talaat. 2012. Device-associated nosocomial infection rates in intensive care units at Cairo University hospitals: First step toward initiating surveillance programs in a resource-limited country. Am. J. Infect. Control. 40(6): e216–20.10.1016/j.ajic.2011.12.01022418610
]Search in Google Scholar
[
El Zowalaty M.E. 2012. Alarming Trend of Antibiotic Resistance in Pseudomonas aeruginosa Isolates. Journal of Pure and Applied Microbiology 6(1): 175–183.
]Search in Google Scholar
[
El Zowalaty M.E., A. Al Thani, T.J. Webster, A.E. El Zowalaty, H.P. Schweizer, G.K. Nasrallah, H.E. Marei and H.M. Ashour. 2015. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiology 10(10) 1683–1706.10.2217/fmb.15.4826439366
]Search in Google Scholar
[
Essack S., C. Connolly and A. Sturm. 2008. Antibiotic use and resistance in public-sector hospitals in KwaZulu-Natal. S. Afr. Med. J. 95(11): 865–70.
]Search in Google Scholar
[
Farra A., S. Islam, A. Strålfors, M. Sörberg and B. Wretlind. 2008. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int. J. Antimicrob. Agents. 31(5): 427–433.10.1016/j.ijantimicag.2007.12.01618375104
]Search in Google Scholar
[
Gerçeker A. A. and B. Gürler. 1995. Invitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 36(4): 707–711.
]Search in Google Scholar
[
Girlich D., T. Naas and P. Nordmann. 2004. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 48(6): 2043–2048.10.1128/AAC.48.6.2043-2048.200441558015155197
]Search in Google Scholar
[
Hamilton-Miller J. 2004. Antibiotic resistance from two perspectives: man and microbe. Int. J. Antimicrob. Agents. 23(3): 209–212.10.1016/j.ijantimicag.2003.12.001
]Search in Google Scholar
[
Hassan A.M., O. Ibrahim and M. El Guinaidy. 2010. Surveillance of antibiotic use and resistance in Orthopaedic Department in an Egyptian University Hospital. Int. J. Infect. Control. 7(1); doi: 10.3396/ijic.V7i1.001.11.10.3396/ijic.v7i1.001.11
]Search in Google Scholar
[
Hong D.J., I.K. Bae, I.-H. Jang, S.H. Jeong, H.-K. Kang and K. Lee. 2015. Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa. Infect. Chemother. 47(2): 81–97.
]Search in Google Scholar
[
Huang S.S., B.J. Labus, M.C. Samuel, D.T. Wan and A.L. Reingold. 2002. Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996–1999. Emerg. Infect. Dis. 8(2): 195–201.
]Search in Google Scholar
[
Jesudason M.V., A. Kandathil and V. Balaji. 2005. Comparison of two methods to detect carbapenemase and metallo-beta-lactamase production in clinical isolates. Indian J. Med. Res. 121(6): 780–783.
]Search in Google Scholar
[
Jones R.N., H.S. Sader and M.L. Beach. 2003. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997– 2001). Int. J. Antimicrob. Agents. 22(6): 551–556.
]Search in Google Scholar
[
Kouda S., M. Ohara, M. Onodera, Y. Fujiue, M. Sasaki, T. Kohara, S. Kashiyama, S. Hayashida, T. Harino and T. Tsuji. 2009. Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the blaIMP-1 gene cassette in Hiroshima. J. Antimicrob. Chemother. 64(1): 46–51.
]Search in Google Scholar
[
Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259): 680–685.10.1038/227680a0
]Search in Google Scholar
[
Landman D., S. Bratu, M. Alam and J. Quale. 2005. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother. 55(6): 954–957.
]Search in Google Scholar
[
Landman D., C. Georgescu, D.A. Martin and J. Quale. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21(3): 449–465.
]Search in Google Scholar
[
Liu Q., X. Li, W. Li, X. Du, J.-Q. He, C. Tao and Y. Feng. 2015. Influence of carbapenem resistance on mortality of patients with Pseudo monas aeruginosa infection: a meta-analysis. Sci. Rep. 5: 11715.10.1038/srep11715
]Search in Google Scholar
[
Livermore D.M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5): 634.
]Search in Google Scholar
[
Mavroidi A., E. Tzelepi, A. Tsakris, V. Miriagou, D. Sofianou and L. Tzouvelekis. 2001. An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum β-lactamase IBC-1. J. Antimicrob. Chemother. 48(5): 627–630.10.1093/jac/48.5.627
]Search in Google Scholar
[
Nishino K. and A. Yamaguchi. 2004. Role of histone-like protein H-NS in multidrug resistance of Escherichia coli. J. Bacteriol. 186(5): 1423–1429.
]Search in Google Scholar
[
Nordmann P. 2010. Gram-negative bacteriae with resistance to carbapenems (in French). Med. Sci. (Paris) 26(11): 950–959.
]Search in Google Scholar
[
Osman K., M. Alabady, N. Ata, N. Ezzeldin and M. Aly. 2010. Genotypic Characterization of Pseudomonas aeruginosa Isolated from Human and Animal Sources in Egypt. Zoonoses and Public Health. 57(5): 329–338.
]Search in Google Scholar
[
Poirel L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J.D. Cavallo and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44(4): 891–897.10.1128/AAC.44.4.891-897.2000
]Search in Google Scholar
[
Poirel L., D. Girlich, T. Naas and P. Nordmann. 2001. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid-and integron-located gene. Anti-microb. Agents Chemother. 45(2): 447–453.10.1128/AAC.45.2.447-453.2001
]Search in Google Scholar
[
Quale J., S. Bratu, J. Gupta and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50(5): 1633–1641.10.1128/AAC.50.5.1633-1641.2006
]Search in Google Scholar
[
Queenan A.M. and K. Bush. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20(3): 440–458.
]Search in Google Scholar
[
Rodriguez-Martinez J.M., L. Poirel and P. Nordmann. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(11): 4783–4788.10.1128/AAC.00574-09
]Search in Google Scholar
[
Shehabi A.A., A.A. Haider and M.K. Fayyad. 2011. Frequency of antimicrobial resistance markers among Pseudomonas aeruginosa and Escherichia coli isolates from municipal sewage effluent water and patients in Jordan. The International Arabic Journal of Antimicrobial Agents. 1(1); doi: 10: 3823/700.
]Search in Google Scholar
[
Song J.H. 2008. What’s new on the antimicrobial horizon? Int. J. Antimicrob. Agents. 32(suppl. 4): S207–213.10.1016/S0924-8579(09)70004-4
]Search in Google Scholar
[
Strateva T., V. Ouzounova-Raykova, B. Markova, A. Todorova, Y. Marteva-Proevska and I. Mitov. 2007. Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J. Med. Microbiol. 56(7): 956–963.10.1099/jmm.0.46986-0
]Search in Google Scholar
[
Strateva T. and D. Yordanov. 2009. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J. Med. Microbiol. 58(9): 1133–1148.
]Search in Google Scholar
[
Suárez C., C. Peņa, L. Gavaldā, F. Tubau, A. Manzur, M. Dominguez, M. Pujol, F. Gudiol and J. Ariza. 2010. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int. J. Infect. Dis. 14: e73–e78.10.1016/j.ijid.2009.11.019
]Search in Google Scholar
[
Tawfik A.F., A.M. Shibl, M.A. Aljohi, M.A. Altammami and M.H. Al-Agamy. 2012. Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates. Burns 38(6): 855–60.10.1016/j.burns.2012.01.005
]Search in Google Scholar
[
Van Delden C. and B. H. Iglewski. 1998. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg. Infect. Dis. 4(4): 551.
]Search in Google Scholar
[
Walsh T.R. 2010. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents. 36(suppl. 3): S8–14.10.1016/S0924-8579(10)70004-2
]Search in Google Scholar
[
Wolter D.J., N. Khalaf, I.E. Robledo, G.J. Vázquez, M.I. Santé, E.E. Aquino, R.V. Goering and N.D. Hanson. 2009. Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 β-lactamases. J. Antimicrob. Chemother. 53(4): 1660–1664.10.1128/AAC.01172-08266307619188398
]Search in Google Scholar
[
Woodford N., J. Zhang, M.E. Kaufmann, S. Yarde, M. del Mar Tomas, C. Faris, M.S. Vardhan, S. Dawson, S.L. Cotterill and D.M. Livermore. 2008. Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum β-lactamases in the United Kingdom. J. Antimicrob. Chemother. 62(6): 1265–1268.
]Search in Google Scholar
